Meningococcal meningitis is a rare but potentially devastating disease which can strike anyone, anywhere in the world. 1
Fortunately, most cases can be prevented through vaccination. 1,3
At Sanofi, we believe in a world where no one should suffer or die from this vaccine preventable disease. 1,2

Meningococcal meningitis mainly affects children under five, adolescents and young adults, but it can happen to anyone at any age1,3

This disease may lead to long-term complications and even death in less than 24 hours1

There are different types of the bacteria that can cause meningococcal meningitis, but vaccines exist for 5 of the most common types1,3

The Race to Defeat Meningitis


Davide, athlete and meningococcal meningitis survivor

WHO Defeating Meningitis by 2030 Global Roadmap

The launch of the first ever global roadmap on meningitis 
marks an historical moment in the fight against meningitis. 

Joining forces against acute bacterial meningitis


For over 45 years, Sanofi has been at the forefront of combating meningococcal epidemics and in driving meningococcal vaccine evolution

Sanofi's Legacy


The fight against meningococcal meningitis is in our hands


Vaccination recommendations vary from
country to country. Learn more

Parents: How to help protect your loved

Adolescents: Don’t let meningococcal
meningitis get in your way


  1. WHO. Meningococcal meningitis. Available at: Accessed February 2021.
  2. ECDC. Factsheet about meningococcal disease. Available at: Accessed February 2021.
  3. Meningitis Research Foundation. What are meningitis and septicaemia. Available at: Accessed February 2021.
  4. Sanofi Pasteur (2020). Meningococcal Disease in Europe: A Rare but Devastating Disease.

MAT-GLB-2100961 v3 - 04/2022